Growth Metrics

Fulgent Genetics (FLGT) Cash from Financing Activities (2016 - 2026)

Fulgent Genetics' Cash from Financing Activities history spans 11 years, with the latest figure at -$44.8 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 301.3% to -$44.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$48.4 million, a 266.71% decrease, with the full-year FY2025 number at -$14.8 million, down 205.12% from a year prior.
  • Cash from Financing Activities hit -$44.8 million in Q1 2026 for Fulgent Genetics, down from -$534000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for FLGT hit a ceiling of -$327000.0 in Q4 2024 and a floor of -$44.8 million in Q1 2026.
  • Historically, Cash from Financing Activities has averaged -$11.1 million across 5 years, with a median of -$2.8 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: crashed 1086.42% in 2022 and later skyrocketed 98.74% in 2024.
  • Tracing FLGT's Cash from Financing Activities over 5 years: stood at -$29.6 million in 2022, then increased by 12.31% to -$26.0 million in 2023, then skyrocketed by 98.74% to -$327000.0 in 2024, then plummeted by 63.3% to -$534000.0 in 2025, then plummeted by 8295.69% to -$44.8 million in 2026.
  • Business Quant data shows Cash from Financing Activities for FLGT at -$44.8 million in Q1 2026, -$534000.0 in Q4 2025, and -$445000.0 in Q3 2025.